MRNA · News · 20260814N

Licensing / Collaboration Deals

Moderna, Inc. · 2026-08-14 · Importance 34 · Surprise 42

Moderna provided Immunovant with a significant upfront payment tied to its IMVT-1402 drug program. The payment is cited as a catalyst alongside anticipated pivotal data readouts for IMVT-1402. The reporting indicates that the collaboration may support Immunovant’s longer-term financial profile despite the company’s current lack of revenue.

Key facts

• Moderna's stock price had a recent 44.2% surge, per TradingView's StockStory summary. source
• The Simply Wall Street article states Immunovant's stock move was attributed in part to 'a significant upfront payment from Moderna.' source
• Moderna was reported to be trading at a forward price-to-sales ratio of 12.3x in the TradingView summary. source